Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens
<p dir="ltr">This study evaluated the potential for antibody‐dependent enhancement (ADE) in serum samples from patients exposed to Middle East respiratory syndrome coronavirus (MERS‐CoV). Furthermore, we evaluated the effect of severe acute respiratory syndrome coronavirus 2 (SARS‐Co...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513542051332096 |
|---|---|
| author | Swapna Thomas (17337925) |
| author2 | Maria K. Smatti (4675852) Haya Alsulaiti (22045127) Hadeel T. Zedan (12535521) Ali H. Eid (5461829) Ali A. Hssain (12535536) Laith J. Abu Raddad (16931811) Giusy Gentilcore (15112577) Allal Ouhtit (526) Asmaa A. Althani (4675855) Gheyath K. Nasrallah (9200525) Jean‐Charles Grivel (22045130) Hadi M. Yassine (4675846) |
| author2_role | author author author author author author author author author author author author |
| author_facet | Swapna Thomas (17337925) Maria K. Smatti (4675852) Haya Alsulaiti (22045127) Hadeel T. Zedan (12535521) Ali H. Eid (5461829) Ali A. Hssain (12535536) Laith J. Abu Raddad (16931811) Giusy Gentilcore (15112577) Allal Ouhtit (526) Asmaa A. Althani (4675855) Gheyath K. Nasrallah (9200525) Jean‐Charles Grivel (22045130) Hadi M. Yassine (4675846) |
| author_role | author |
| dc.creator.none.fl_str_mv | Swapna Thomas (17337925) Maria K. Smatti (4675852) Haya Alsulaiti (22045127) Hadeel T. Zedan (12535521) Ali H. Eid (5461829) Ali A. Hssain (12535536) Laith J. Abu Raddad (16931811) Giusy Gentilcore (15112577) Allal Ouhtit (526) Asmaa A. Althani (4675855) Gheyath K. Nasrallah (9200525) Jean‐Charles Grivel (22045130) Hadi M. Yassine (4675846) |
| dc.date.none.fl_str_mv | 2024-04-29T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1002/jmv.29628 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Antibody_dependent_enhancement_ADE_of_SARS_CoV_2_in_patients_exposed_to_MERS_CoV_and_SARS_CoV_2_antigens/29898503 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Immunology Health sciences Public health COVID-19 Vaccination Pseudovirus Assay Neutralizing Antibodies Cross-Reactive Immunity Viral Pathogenesis Post-Infection Immunity |
| dc.title.none.fl_str_mv | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">This study evaluated the potential for antibody‐dependent enhancement (ADE) in serum samples from patients exposed to Middle East respiratory syndrome coronavirus (MERS‐CoV). Furthermore, we evaluated the effect of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination on ADE in individuals with a MERS infection history. We performed ADE assay in sera from MERS recovered and SARS‐CoV‐2‐vaccinated individuals using BHK cells expressing FcgRIIa, SARS‐CoV‐2, and MERS‐CoV pseudoviruses (PVs). Further, we analyzed the association of ADE to serum IgG levels and neutralization. Out of 16 MERS patients, nine demonstrated ADE against SARS‐CoV‐2 PV, however, none of the samples demonstrated ADE against MERS‐CoV PV. Furthermore, out of the seven patients exposed to SARS‐CoV‐2 vaccination after MERS‐CoV infection, only one patient (acutely infected with MERS‐CoV) showed ADE for SARS‐CoV‐2 PV. Further analysis indicated that IgG1, IgG2, and IgG3 against SARS‐CoV‐2 S1 and RBD subunits, IgG1 and IgG2 against the MERS‐CoV S1 subunit, and serum neutralizing activity were low in ADE‐positive samples. In summary, samples from MERS‐CoV‐infected patients exhibited ADE against SARS‐CoV‐2 and was significantly associated with low levels of neutralizing antibodies. Subsequent exposure to SARS‐CoV‐2 vaccination resulted in diminished ADE activity while the PV neutralization assay demonstrated a broadly reactive antibody response in some patient samples.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Medical Virology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/jmv.29628" target="_blank">https://dx.doi.org/10.1002/jmv.29628</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_dd7551233a3049db4af16d2436d73dca |
| identifier_str_mv | 10.1002/jmv.29628 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29898503 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigensSwapna Thomas (17337925)Maria K. Smatti (4675852)Haya Alsulaiti (22045127)Hadeel T. Zedan (12535521)Ali H. Eid (5461829)Ali A. Hssain (12535536)Laith J. Abu Raddad (16931811)Giusy Gentilcore (15112577)Allal Ouhtit (526)Asmaa A. Althani (4675855)Gheyath K. Nasrallah (9200525)Jean‐Charles Grivel (22045130)Hadi M. Yassine (4675846)Biomedical and clinical sciencesClinical sciencesImmunologyHealth sciencesPublic healthCOVID-19 VaccinationPseudovirus AssayNeutralizing AntibodiesCross-Reactive ImmunityViral PathogenesisPost-Infection Immunity<p dir="ltr">This study evaluated the potential for antibody‐dependent enhancement (ADE) in serum samples from patients exposed to Middle East respiratory syndrome coronavirus (MERS‐CoV). Furthermore, we evaluated the effect of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination on ADE in individuals with a MERS infection history. We performed ADE assay in sera from MERS recovered and SARS‐CoV‐2‐vaccinated individuals using BHK cells expressing FcgRIIa, SARS‐CoV‐2, and MERS‐CoV pseudoviruses (PVs). Further, we analyzed the association of ADE to serum IgG levels and neutralization. Out of 16 MERS patients, nine demonstrated ADE against SARS‐CoV‐2 PV, however, none of the samples demonstrated ADE against MERS‐CoV PV. Furthermore, out of the seven patients exposed to SARS‐CoV‐2 vaccination after MERS‐CoV infection, only one patient (acutely infected with MERS‐CoV) showed ADE for SARS‐CoV‐2 PV. Further analysis indicated that IgG1, IgG2, and IgG3 against SARS‐CoV‐2 S1 and RBD subunits, IgG1 and IgG2 against the MERS‐CoV S1 subunit, and serum neutralizing activity were low in ADE‐positive samples. In summary, samples from MERS‐CoV‐infected patients exhibited ADE against SARS‐CoV‐2 and was significantly associated with low levels of neutralizing antibodies. Subsequent exposure to SARS‐CoV‐2 vaccination resulted in diminished ADE activity while the PV neutralization assay demonstrated a broadly reactive antibody response in some patient samples.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Medical Virology<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1002/jmv.29628" target="_blank">https://dx.doi.org/10.1002/jmv.29628</a></p>2024-04-29T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1002/jmv.29628https://figshare.com/articles/journal_contribution/Antibody_dependent_enhancement_ADE_of_SARS_CoV_2_in_patients_exposed_to_MERS_CoV_and_SARS_CoV_2_antigens/29898503CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/298985032024-04-29T09:00:00Z |
| spellingShingle | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens Swapna Thomas (17337925) Biomedical and clinical sciences Clinical sciences Immunology Health sciences Public health COVID-19 Vaccination Pseudovirus Assay Neutralizing Antibodies Cross-Reactive Immunity Viral Pathogenesis Post-Infection Immunity |
| status_str | publishedVersion |
| title | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| title_full | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| title_fullStr | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| title_full_unstemmed | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| title_short | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| title_sort | Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens |
| topic | Biomedical and clinical sciences Clinical sciences Immunology Health sciences Public health COVID-19 Vaccination Pseudovirus Assay Neutralizing Antibodies Cross-Reactive Immunity Viral Pathogenesis Post-Infection Immunity |